Jon Pycock, President of BEVA said: "A significant number of BEVA members have young children and we want to make it as easy as possible for them to enjoy Congress without having to worry about making separate plans for childcare at home. We have already had a great response to the idea and it’s looking like the crèche is going to be very popular."
The theme of this year's Congress is helping horse vets celebrate the benefits and pleasures of their job.
In addition to the social and scientific programme at Congress, there will be special sessions on reproduction, non-clinical aspects of being a vet, succession planning, a moral maze debate on specials manufacturing and role play demonstrations on how to manage difficult situations in practice.
Dr Juan Samper, Associate Dean for students and instruction at the University of Florida College of Veterinary Medicine will be giving the plenary lecture on the challenges and opportunities in equine practice.
There will also be specific lecture streams for veterinary nurses, equine dental technicians and farriers.
For more information on the BEVA Congress crèche or to reserve your child's place, contact Jocelyn@beva.org.uk or call 01638 723558. BEVA says places are limited so early booking is advised.
The BEVA Congress programme can be viewed at www.bevacongress.org.
Researchers at the University of Edinburgh’s Royal (Dick) School of Veterinary Studies are to start testing whether a compound of cooling chemicals, extracted from mint, can be used to treat laminitis, a condition which affects seven per cent of the British horse population.
The new project, funded by The Horse Trust and led by Professor Sue Fleetwood-Walker, builds on recent work that revealed for the first time that, there is significant nerve damage, as well as inflammation, within the hoof of laminitic horses. This explains why anti-inflammatory drugs are so ineffective in treating the pain of chronic laminitis and highlights the need for therapies to treat nerve injury-induced or ‘neuropathic’ pain in horses.
Prof Fleetwood-Walker’s team discovered in 2006 that the ‘mint’ chemicals have a pain–killing effect in laboratory studies of chronic pain. They will now investigate whether this synthetic treatment could help horses with laminitis.
Their study, which was published in the research journal PeerJ at the end of last year1, investigated the effects of insulin on equine hoof lamellar cells in the laboratory.
The researchers say that high levels of insulin have been known for some time to cause acute endocrine laminitis, seen when ponies and certain types of horses graze lush pasture or consume a starch- or sugar-rich diet, or when they develop Cushing’s syndrome.
Many ponies and horses at risk of the condition produce large spikes of insulin in their blood stream after consuming meals high in non-structural carbohydrates (in particular starch and simple sugars) which indicates that this could be the way in which they succumb to acute endocrine laminitis.
The mechanism by which insulin can cause effects in the foot leading to laminitis has been the subject of much debate in recent years.
Hormones like insulin must interact with a specific receptor on the surface of cells in order to produce their effects. What has confused researchers in the past is that there appear to be no insulin receptors on the hoof lamellar cells (these cells give the lamellar tissues their strength and changes to their growth or structure weaken the bonds and cause laminitis).
The researchers considered the close similarities between insulin and a growth factor hormone called insulin-like growth factor -1 (IGF-1). There are receptors for IGF-1 on the lamellar cells, and the researchers speculated that high concentrations of insulin might be able to cross-stimulate these cells by activating the IGF-1 receptors. To investigate this possibility PhD student Courtnay Baskerville, together with her supervisor Professor Simon Bailey, developed a method for culturing lamellar epithelial cells in the laboratory, and incubated them with increasing concentrations of insulin.
They found that high concentrations of insulin stimulated the cells to proliferate. Furthermore, this effect could be prevented using an antibody that specifically blocks only the IGF-1 receptor. Further downstream effects within the cells were also shown. The changes seemed to occur mainly at very high concentrations of insulin. Similar concentration levels can be seen in ponies and horses with insulin dysregulation linked to Equine Metabolic Syndrome, but are not commonly seen in normal horses that are considered to be at lower risk of laminitis.
Further work is now ongoing to determine exactly how these cellular changes induced by sustained high insulin concentrations might cause laminitis. However, it seems that targeting the IGF-1 receptor may be an option for developing new drugs to prevent and treat laminitis.
Professor Simon Bailey said: "The information gathered in this study provides the equine industry worldwide with valuable insights into the causes of the common and serious condition of laminitis. The research group would like to acknowledge the support of the Waltham Centre for Pet Nutrition, in particular the involvement of Professor Pat Harris.”
Reference
Themed 'Controlling Disease Threats at Home and from Abroad’, this year's conference will highlight the increasing importance of OVs in safeguarding the UK’s international trade and in protecting human health through disease surveillance and control.
The conference programme includes dedicated lecture streams aimed at large animal, small animal and equine practitioners. Improve says that lecture content has been tailored to cover areas of key relevance for more than 8,000 OVs due to revalidate their qualifications in March 2019. The programme also includes interactive workshops, including drop-in question and answer sessions offering practical advice and guidance on the revalidation process.
An exhibition of products and services for OVs runs alongside the conference.
David Babington MRCVS, Business Development Director at Improve, said: "This conference remains the only event dedicated to the needs of OVs. They receive industry updates from leading figures in the veterinary sector, attend lectures on OV work from experts and, in so doing, work towards their CPD revalidation requirements. We’re currently finalising a packed programme for this year’s conference and urge OVs to take advantage of our time-limited Early Bird offers and register without delay."
For more information on the Official Veterinarian Conference and Exhibition or to register visit: www.officialvet.com
Merial Animal Health is inviting practitioners to submit original clinical pain management cases for The Previcox & Equioxx European Clinical Case Award for Excellence.
Set up last year, the award recognises excellence in pain management in companion animals and horses. Submitted cases will be evaluated for successful management of pain associated with osteoarthritis, surgery or other conditions in companion animals and horses using firocoxib.
Two winners will be selected and each awarded €1,000 and an invitation to present their clinical case during Merial's next European Pain Management Symposium in 2012, with all travel and accommodation expenses paid.
Open to all veterinary practitioners, the deadline for submission is December 1st 2011. For an application form please email agate.vanopstal@merial.com
The successful candidates, who completed their studies during 2020 and passed the examination in November, are Lucy Wilson (pictured right), from Equibreed UK, Reading, Vanessa Austin, who works at at Vets4Pets, Northampton, and Donna Johnson, the Clinical Services Manager at The Pet Vet, Barnsley.
Lucy said: “I chose to do the CVPM to cement my knowledge of how to run our practice to the best of my ability and to provide the highest level of support to my colleagues. The CVPM resources, syllabus and experience have given me a thorough understanding of my skills and areas to develop. I cannot recommend the experience highly enough.”
Chair of the VMG Certification and Training Committee, Philippa Davies, said: “The CVPM exam tests candidates’ skills in operational management, prioritising, strategy, and thinking on your feet. It’s a gruelling assessment and holders are an elite group. We are delighted to welcome Vanessa, Donna and Lucy and congratulate them on their achievement.”
For more information, visit: https://www.vetmg.com/education/cvpm/
Vetoquinol UK Ltd is launching a dedicated large animal/equine sales force on the 1st July.
The company says the move reflects the change in cattle and equine veterinary practice to become specialists.
Vetoquinol's large animal brands include: Marbocyl®, Sedalin®, Equistro®, Tolfine®, Pro Rumen and Locatim®.
The new team comprises:
The new sales team will be managed jointly by Hugh Gibson and Stuart Wade.
For further information or to make an appointment please contact your local Territory Manager direct or telephone 01280 825424
Wiley has announced the joint online publication of a special issue of 22 ophthalmology papers from Equine Veterinary Journal, Equine Veterinary Education and Veterinary Ophthalmology.
Clinical equine ophthalmology: The current state of the art brings together papers on some of the most significant advances in equine clinical ophthalmology into a single issue to make them more readily available to a wider audience. The issue contains information of direct relevance to all sectors of the veterinary profession from general practitioners and specialists to researchers, surgeons and students, covering common diseases, surgical procedures and outcomes.
The new publication was devised and compiled by a panel of guest editors comprising Mary Lassaline, member of the Veterinary Ophthalmology Editorial board and Veterinary Ophthalmologist in the Department of Surgical and Radiological Sciences at UC-Davis School of Veterinary Medicine, California, David A. Wilkie, Editor of Veterinary Ophthalmology and Professor at Veterinary Clinical Sciences Comparative Ophthalmology Ohio State University, Tim Mair, Editor of Equine Veterinary Education based at Bell Equine Veterinary Clinic, Kent and Celia M Marr, Editor of Equine Veterinary Journal, based at Rossdales, Newmarket.Mary Lassaline said: "The goal was to provide broad access to the most current information applicable to every stratum of the equine veterinary profession. Subsequently, a salient feature is that many of the papers included are collaborations between veterinary ophthalmologists with a special interest in horses, equine practitioners with a special interest in ophthalmology, private practitioners and those in academia, and academicians from different institutions."
Subjects covered include seven papers on new approaches to the diagnosis and treatment of ulcerative and non-ulcerative keratitis in the horse. There are three articles on novel approaches to corneal surgery and a further three on corneal neoplasia. Six papers provide valuable data regarding long-term outcomes following surgical intervention for Equine Recurrent Uveitis (ERU), glaucoma, and cataracts. Finally, three articles present new information regarding retinal and orbital disease.
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "The key purpose of the EVJ is to disseminate information to help the enhancement of specialist knowledge at every level of the veterinary profession. By collating the most important and up-to-date ophthalmology research into one easy resource the new special issue does exactly that."The ophthalmology special issue is available free online at: http://bit.ly/1bi0RG0
Zoetis, formerly Pfizer Animal Health has launched Ovatec Plus, which it claims will make equine faecal collection and in-practice worm count testing quicker and easier.
Ovatec Plus is designed to facilitate the in-house detection of worm burdens by enabling the coproscopic examination of parasite eggs, larvae and cysts. Zoetis says the built-in sample collection scoop allows for hands-off, quick, clean sample collection and controlled sample size, while the built-in cap, which can be written on for easy identification, snaps shut to seals the contents safely for contamination-free transport.
The system is based on zinc sulphate flotation technology, with a flotation time of ten minutes to provide rapid analysis. The Ova-Spin feature will break up difficult samples. The positive-locking filter chamber prevents any spill of test samples and reduces operator exposure to potential hazards. The overflow reservoir prevents overfills leaking onto the lab bench.
Zoetis says the high sensitivity and excellent specificity of Ovatec Plus enable informed treatment decisions to be made. A study has shown that samples proving negative with Ovatec Plus provide 95% certainty that the sample is <150epg and 100% certainty that the sample is <250epg, which means treatment may not be necessary1. Samples that prove positive, with one or more eggs seen, can be verified using a quantitative technique if needed, alternatively treatment may be indicated.
Ben Lacey, equine business unit manager at Zoetis, said: "Ovatec Plus is an excellent addition to our equine worm control portfolio. It's ideal for use in many test situations, giving a quick, easy and convenient solution."
To find out more, speak to your Zoetis Account Manager, call 0845 300 8034 or email CustomerSupportUK@zoetis.com.
The Disciplinary Committee (DC) of the Royal College of Veterinary Surgeons last week issued a reprimand to a veterinary surgeon for reckless certification of an equine passport, having found her to have been "wholly indifferent" as to whether the horse had been vaccinated properly against equine influenza.
Eleri Wyn Jones graduated from the University of Liverpool and qualified as a veterinary surgeon in 2006, before joining The Veterinary Practice on Bala Road in Dolgellau, Gwynedd, where she was also an authorised Local Veterinary Inspector (LVI). The principal of that practice is Iwan Parry, who himself was the subject of a DC hearing involving false certification earlier this year, for which he received a one-month suspension from the Register.
The Committee heard how, in late 2007, as Ms Jones was leaving the practice to begin her rounds, she was asked by a non-veterinary colleague to certify in a horse passport that two vaccinations for equine influenza had been administered. The horse in question was being liveried by a regular client of the practice, to whom the practice regularly dispensed veterinary vaccines (although Ms Jones was unaware of this), but had been recently purchased by someone who was not a registered client.
In evidence, Ms Jones admitted the certification process took her only 30 seconds and that she did not obtain any further information about the certification, either from clinical or non-clinical colleagues; nor did she check any other documentation before signing the passport, but assumed the vaccinations had been administered by a veterinary colleague. The Committee had to decide whether Ms Jones had acted recklessly, and to do so, Ms Jones' Counsel suggested the Committee would need to be satisfied that she "did not care less" whether or not the vaccinations had been given by a veterinary surgeon before signing the passport.
In reaching its decision, the Committee took into account the fact Ms Jones, on her own evidence, was generally familiar with RCVS guidance on certification and, as an authorised Local Veterinary Inspector, had certification training. It stated: "Whilst we recognise that Ms Jones received little or no mentoring from Mr Parry, we are satisfied that she would have been aware of the importance of veterinary certification. She was also aware that Mr Parry had been suspended as an LVI, due to certification issues, which had affected her own authorisation."
In view of these facts, and that Ms Jones made no attempt to obtain verification from any other source despite knowing she had not performed the vaccinations herself, the Committee decided that Ms Jones had been "wholly indifferent" to proper vaccination procedures and was therefore guilty of disgraceful professional conduct for reckless certification.
In reaching its decision on sanction, the Committee wished to remind members that cases involving improper certification would ordinarily result in suspension or removal from the Register. "We strongly disapprove of the circumstances in which Ms Jones certified this horse.
Clients, and external bodies, are entitled to rely upon the integrity of the veterinary surgeon in not certifying that horses have been vaccinated unless they have carried out the vaccinations themselves or have obtained full and proper evidence that vaccination has been carried out by another veterinary surgeon," it said.
In mitigation, however, the Committee took into account Ms Jones' age and inexperience, her previously good record, her good character and the significant number of supporting references from colleagues and clients alike. It was also mindful that any sanction's main purpose was to protect animal welfare and maintain public confidence in the profession, rather than to punish.
Nigel Swayne, chairing the Committee, concluded: "This is not a case where undertakings for training or monitoring are required. This isolated incident was a fateful misjudgement on a single occasion. We consider that the sanction most proportionate to the nature and extent of the charge, the public interest and the interests of Ms Jones is a reprimand."
The range includes:
Fluodrop (the first fluorescein product specifically designed for veterinary use)
Ocryl - an ocular and periocular cleanser that can also be used to reduce and prevent unsightly tear staining
Ocular lubricants (carbomer and hyaluronic acid based)
Clerapliq – a novel molecule to the UK veterinary market that is used to help restore and regenerate the corneal extracellular matrix
The products will be supported with a selection of materials to help vets, nurses and pet owners in the maintenance of corneal health, including diagnosis and treatment guidelines, anatomical guides, posters and client educational and treatment aids to help with compliance.
William Peel MRCVS, product manager at TVM-UK said: "Our Corneal Focus Range is an exciting way to expand on our product portfolio following the successful introduction of our ‘Anti-tox’ range.
"With ‘Anti-tox’ we successfully managed to make vets and nurses lives easier by providing education and materials alongside a great range of products to help when dealing with poisoning cases in practice. We also attempted to make clients more aware of the dangers of poisoning in pets.
"We hope to emulate this approach and success with our Corneal Focus Range – by developing a wealth of materials for vets, nurses and clients to aid them in managing and understanding ophthalmology cases – and by providing quality products."
TVM UK will be showcasing its new products and support services at the London Vet Show (stand P40) this November.
For more information, visit: http://www.tvm-uk.com/
The session will be conducted in the style of the BBC Radio 4 Moral Maze discussion programme, with panelists and witnesses arguing for and against the viewpoint corporatisation is inevitable and will benefit vets and their clients.
Moderated by Madeleine Campbell, Keith Chandler and Karl Holliman will argue for corporatisation and Andrew Harrison and Tim Greet will be against. They will call upon a series of 'witnesses' for detailed questioning before the topic is more broadly debated.
CVS, the UK’s biggest veterinary group now owns more than 410 veterinary practices, of which over 30 are specifically equine or mixed practices.
The latest equine acquisitions include Bell Equine, a one-site Equine Referral Hospital in Kent, in January 2017 and Severn Edge Veterinary Group, a mixed practice with 12 sites in Shropshire, including a six-vet dedicated equine practice, in April 2017.
One line of argument says that the commercial and business advantages of a corporate, together with their scale and diversity, can give veterinary surgeons greater potential for a more flexible career path and advancement within the industry, and a more sustainable working career in equine practice.
On the flip side, there's the removal of any opportunity to buy into ownership, reduced decision-making ability because of adherence to corporate procedures, extra paperwork, longer approval processes and an increased emphasis on the bottom line.
David Mountford, Chief Executive of BEVA said: "The auditorium is usually full to bursting for our Moral Maze sessions because they bring a broader and more engaging dimension to important topics. The statement Corporatisation of equine practices is inevitable and will benefit vets and their clients is bound to generate some stimulating and possibly heated debate."
This year's BEVA Congress will be held at Liverpool Arena Convention Centre, and anyone who registers before 3rd August will receive significantly reduced booking fees.
For more information, visit: www.beva.org.uk.
If you’re a show-jumping vet, you might like to take part in the first-ever international veterinary-only riders competition – held in the beautiful region of Lure at the foot of the Vosges in France.
The French association of veterinary riders (AFVC) invites all veterinary riders to contend for the First World Veterinary Equestrian Show Jumping Cup, to be held from July 3 to 6, 2008.
The event is open to all qualified veterinarians and veterinary students, who may participate with or without their own horse.
The event will include four show-jumping competitions (one per day), while the social programme consists of a Gala evening (Friday), a dinner-dance (Saturday, sponsored by Merial) and a Sunday lunch (major sponsor of the event: Equistro / Vétoquinol).
The veterinary show-jumping event will coincide with France’s 6th Grand National show-jumping competition, also held in Lure.
For further information, please contact: David Smart DVM, david.smart@vetoquinol.com or your local Vétoquinol representative.
Boehringer Ingelheim Vetmedica has launched Buscopan 20mg/ml injection, an antispasmodic treatment for use in cases of equine colic, and an aid to the symptomatic treatment of calf scour.
A sister product to Buscopan Compositum which contains both an antispasmodic and a non-steroidal component, Buscopan 20 contains only the antispasmodic component - hyoscine butylbromide.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Our customers have been telling us for some time that they would really welcome a Buscopan formulation without an NSAID for use in horses and cattle. I'm pleased to say that it's finally here and I'm sure that Buscopan 20 will be a very welcome addition to the armoury of both equine and cattle practitioners."
Buscopan 20 is supplied in a 50ml multi-dose bottle, and is available in veterinary wholesalers now.
For further information, please call 01344 746959.
The survey is open to all veterinary surgeon members and participants will be entered into a free prize draw to win £500 of BEVA CPD vouchers.
As we all know, antibiotic resistance is increasing throughout human and veterinary medicine, and there are few new antibiotics being produced. As BEVA says, it’s therefore imperative for vets to protect the usage of antimicrobials to maintain their effectiveness for the future.
To that end, the purpose of the survey is to help fill in gaps in knowledge about how antimicrobials are being used and also the current landscape of resistant infections encountered in equine practice.
The survey has been designed by Amie Wilson and Dr Gina Pinchbeck at the University of Liverpool and Tim Mair the incoming President of BEVA.
Tim said: "This survey will assess any changes in prescribing of antimicrobials in equine practice since the last survey in 2009. In addition, we will collect data on the current frequency and types of antimicrobial resistant infections seen by clinicians in all areas of equine practice and what infection control and audit practices are currently using to combat this."
The survey results should lead to a greater understanding of the role of antimicrobial treatment in the overall epidemiology of antimicrobial resistance in horses and will help protect antibiotics for the future of equine and human health.
To take part in the survey, visit: https://liverpool.onlinesurveys.ac.uk/beva-questionnaire-2019-final
The results will be announced to coincide with European Antibiotic Awareness Day on 18 November 2019.
If you have any questions about the survey you can contact the researchers direct: Amie Wilson, University of Liverpool A.wilson3@liv.ac.uk; Dr Gina Pinchbeck, University of Liverpool ginap@liv.ac.uk; Tim Mair, British Equine Veterinary Association tim.mair@btinternet.com
Dr Neil Bryant from the AHT, who is leading the research, said: "EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world. It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease."
As a viral infection, EHV can cause respiratory disease, abortion or fatal illness in new born foals and neurological disease in adult horses, with signs ranging from slight wobbliness through to complete paralysis. The disease can strike any horse at any time because the virus, like other herpesviruses (such as the cold sore virus in humans), becomes dormant within most horses early in their life. It then re-emerges when the animal is later stressed such as when transported or mixed with new horses. A seemingly healthy pregnant mare may suddenly, and without warning, abort her unborn foal or may show signs of respiratory disease including mild fever, coughing and discharge from the nose. A horse which appears fit and well may suddenly show abnormalities when walking and within hours may be unable to stand.
Despite the potential severity and impact of outbreaks, there is still no vaccine that is licensed to protect against the neurological form of the disease and abortions still occur in highly vaccinated horse populations. The AHT says protection afforded by existing vaccines currently in use is sub-optimal, something that was highlighted by the 2016 abortion storm in Hertfordshire in fully vaccinated animals.
Neil added: "We have become aware of a pressing need for progress towards a new and improved EHV-1 vaccine. Just last month, the AHT was again called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in premises in Yorkshire and Suffolk."
To that end, the charity has now established the Equine Industries EHV Vaccine Steering Group. Chaired by Professor Joe Brownlie of the RVC, the steering group includes world-renowned experts on both human and equine herpes viruses from a number of research establishments, who have concluded that the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.
After securing funding from a large number of organisations, including the Alborada Trust, EBM Charitable Trust, Horserace Betting Levy Board and the Racing Foundation, Paul Mellon Estate, Thompson Family Charitable Trust, Coolmore Ireland, Newsells Park Stud, Thoroughbred Breeders’ Association and Juddmonte Farms, the AHT has begun its five-year research programme.
Neil added: "We’re at the beginning of a very exciting and potentially ground-breaking vaccine development. Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs. We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1."
The survey will assess vets’ experiences of the disease, biosecurity and the role of vaccination to help prevent strangles.
It includes questions on the number of strangles cases diagnosed in the last year, how the diagnosis was reached and in what instances they would recommend strangles vaccination.
The survey, which is approximately two minutes long, is at: https://forms.office.com/e/wH1UeVFmVW.
All participants will be entered into a prize draw for a £50 Amazon voucher.
For further information on Strangles Awareness Week: https://www.redwings.org.uk/strangles/strangles-awareness-week.
BlueSky says that conventional treatment for equine sarcoids, which are induced by tumour antigens E6 and E7 of the bovine papillomavirus, have only limited effect and typically result in the recurrence of the tumours.
However, research published by the company in PLoSONE1 showed that sarcoids treated with delNS/E6E7 were completely and permanently eliminated.
For the study, 29 horses were treated with different regimes involving direct injection into the tumours over three years.
Visible and very significant regression of the sarcoids was achieved in 20 of the treated horses, and 100% regression of the sarcoids in 10 equine patients.
Thomas Muster, CEO of BlueSky Immunotherapies said: "The complete elimination of very aggressive and difficult-to-cure equine sarcoids is yet another important proof of the potential offered by our delNS platform."
In addition, the systemic delNS-mediated immune stimulation eliminated non-injected sarcoids and the papillomavirus that caused the sarcoids.
Thomas added: "We are therefore confident that we will also be able to successfully heal and/or eliminate the cervical tumours of the women enrolled in the clinical trials currently under way."
This year the event delivered more than 90 hours of CPD lectures, workshops and practicals across six separate streams, over three days. Over 100 veterinary industry leaders showcased their wares in the commercial exhibition hall and there were a number of social events for delegates.
Delegates awarded the scientific programme an average score of 4.7 out of 5 stars, and 94% of delegates said they will put what they learnt into practice and use it in their day-to-day role. 94% also said Congress was good value for money.
Swissvet, a company which makes power dentistry equipment, won the Veterinary Practice Best New Exhibitor Award. CEO Dr Ruedi Steiger said: We have distributors throughout Europe, but it is the first time Swissvet has exhibited at BEVA. It has been a fantastic experience and I am thrilled to have won this award. I definitely plan to come back next year."
Next year’s BEVA Congress will be held in Birmingham from 9-12 September 2020. For further information visit www.beva.org.uk.
Photo: David Boughey
Petplan Equine is now seeking nominations for the Equine Vet of the Year Award 2009, an award to recognise vets that go above and beyond with their care of horses and their owners.
Andrew Dobson of The Barn Equine and Large Animal Practice in Great Wakering, Essex, is the current 2008 Equine of the Year. He was nominated by a number of his grateful clients and their glowing testimonials impressed the judges enough to give him the edge over his closest rivals for the title.
The 37 year old qualified in 1999 and for the last four and a half years has run his own practice. His involvement with horses evolved from a desire to work with large animals and the outdoor life it would bring.
Andrew said: "I was absolutely stunned. I'm so honoured and amazed to have received the Petplan Equine Vet of the Year award. I really enjoy what I do and would like thank all my clients, Petplan Equine and The Animal Health Trust for their support."
If you feel you know a vet that displays equine clinical excellence and fantastic customer care you can nominate online by visiting www.petplanequine.co.uk/events Nominations close 3rd October 2009. An independent panel will judge the nominations and the winning vet will be announced at the Animal Health Trust UK Equestrian Awards in London, in November 2009.
Pat is the head of the Equine Studies Group at Waltham Petcare Science Institute and an internationally renowned authority on equine nutrition from both veterinary and academic perspective.
Her courses, book publications and webinars are aimed at providing practising equine vets with the latest knowledge and essential know-how on equine nutrition, whether for performance horses, leisure animals or the retired family pony.
Earlier this month Pat was one of several speakers at the British Equine Veterinary Association’s CPD course: From superfoods to supplements: How to know more than the owner.
Earlier this year she co-edited and co-authored two chapters of Veterinary Clinics Equine Practice: Nutrition: 1) What would be good for all veterinarians to know about equine nutrition, and 2) Nutritional considerations when dealing with an obese adult equine.
Next month she will chair a panel discussion titled Nutritional Management of the Competitive Equine Athlete for Vets through VetPD.
In the autumn she will be one of several speakers at the Mars Equestrian Equine Veterinary Continuing Education Series focusing on senior, obese and laminitic horses.
For more information, visit: www.spillers-feeds.com
The charity says that it had already been suffering a period of 'dire financial constraints' and the economic effects of coronavirus are now having a direct effect on funding.
The charity's Trustees and Executive Committee is still trying to find emergency funding to try and save the organisation, failing which it will close on the 31st March.
Equip EHV 1,4 is licensed for the active immunisation of horses to reduce clinical signs due to infection with Equine Herpesvirus 1 and 4 and to reduce abortion caused by EHV-1 infection.
Zoetis says it has already communicated directly with veterinary surgeons to inform them that Equip Rotavirus will be out of stock from the end of November 2017 until mid-2018.
During this time an imported vaccine for Rotavirus, will be available to provide an interim solution until supply is restored.
Practices wanting to buy the alternative imported Rotavirus vaccine will need to apply to the VMD for a Special Treatment Certificate (STC).
The company says it acknowledges the concern and frustration this causes its customers and wants to reassure the equine community that it is working diligently to restore the supply of Equip Rotavirus as soon as possible.
For more information, contact your Zoetis account manager or Zoetis technical team.
Zoetis has announced the introduction of Equimidine solution in a 50% larger plastic bottle.
The company says the new 15ml multi-dose presentation, now in plastic rather than glass, offers greater safety, as well as cost-saving advantages to practices.
Equimidine, containing 10mg/ml detomidine hydrochloride and methyl parahydroxybenzoate 1 mg/ml as a preservative, is a clear solution for intravenous injection. It has sedative and analgesic properties and is indicated for use either alone or in combination with butorphanol to facilitate the handling of horses for clinical examinations, minor surgical procedures and other manipulations. It can also be used with ketamine for short duration general anaesthesia for surgical procedures such as castration.
According to the company, the new 15ml plastic bottle is more cost-effective per dose than the old 10ml glass vial. It is also safer to use as the bottle is less likely to break if accidentally dropped. The multi-dose facility involves a tightly fitted rubber bung through which a sterile needle can be inserted to withdraw each dose.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "The new presentation provides practical benefits for vets and the larger bottle size means the product is now even more cost-effective."
For more information, speak to your Zoetis Account Manager, refer to the SPC or contact Zoetis Customer Support on 0845 3008034.
Kruuse has launched a range of seven specialized sterile surgical disposable drapes and gowns developed for the surgery team working in equine clinics or hospitals.
The company says its new surgical sets have been designed so they include a comprehensive set of sterile drapes, towels, instrument covers and adhesive tapes needed to perform particular procedures:
Andrew Groom, Managing Director, Kruuse UK Ltd. said: "This exciting new range of products increase the Kruuse's equine product portfolio and develop further our commitment to provide specialist species available products to support the veterinary practitioner."